ANALYSIS OF GENE EXPRESSION PROFILE CHANGES FOLLOWING THERAPY WITH 4-[(3-ETHOXY-3-OXOPROPANOYL) AMINO] BENZOIC ACID IN EXPERIMENTAL CHRONIC HEART FAILURE

Аннотация

Topicality. Chronic heart failure (CHF) is associated with systemic oxidative stress and significant impairment of cellular metabolism, contributing to damage to target organs, particularly the kidneys. Current therapeutic approaches have limited efficacy in correcting these metabolic disorders. Succinate dehydrogenase (SDH) inhibitors, such as 4-[(3-ethoxy-3-oxopropanoyl) amino] benzoic acid (etmaben), are considered potential agents for metabolic therapy; however, their molecular mechanisms of action in established CHF remain poorly understood.